220THYMOQUINONE (TQ) INHIBITS INFLAMMATORY RESPONSE IN AN ALZHEIMER'S DISEASE RAT MODEL BY INHIBITING TNFPRODUCTIONA promising therapeutic agent for Alzheimer's disease is thymoquinone (TQ) in Nigella sativa. In a rat model of AD, where aggregated A? (42) was infused into the hippocampus, TQ was administered orally at a dose of 25 mg/kg/day. Cognitive function was assessed using the Morris Water Maze task, and levels of inflammatory cytokines in the animals’ brain were measured. Protein expression related to synaptic plasticity, apoptosis, and neuronal migration was examined. On Day 3, the A? (42)-infused group exhibited cognitive impairment compared to the control group, but TQ administration mitigated this effect. Levels of TNF-alpha, IL-1 alpha, and IL-1 beta did not differ significantly between groups. A? (42) infusion slightly reduced IFN-? levels, which were restored by TQ treatment. TQ improved memory performance, reduced inflammation (indicated by decreased IL-1 beta levels), and increased DCX protein levels, suggesting enhanced neurogenesis. Both A? (42) groups showed lower MAP2 and PARP protein activation, indicating potential neuroprotective effects. Furthermore, a positive correlation was observed between IL-1 beta and DCX levels. These findings suggest that TQ may benefit AD by promoting neurogenesis, modulating IFN-? levels, and reducing inflammation. TQ shows promise as a therapeutic agent for AD by targeting neuroinflammation and neuroprotection pathways. Further research is needed to understand the underlying mechanisms and assess the translation of these findings to human studiesramyakrishna.ravuri@gmail.comResearch1322023IFN-? levels,Mitogen-Activated Protein Kinase2,protein Poly (ADP-ribose) PolymeraseRamya Krishna RavuriBhaskar pharmacy College Department Pharmacology